Is Bolt Biotherapeutics Stock a Good Investment?
Bolt Biotherapeutics Investment Advice | BOLT |
- Examine Bolt Biotherapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Bolt Biotherapeutics' leadership team and their track record. Good management can help Bolt Biotherapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Bolt Biotherapeutics' business and its evolving consumer preferences.
- Compare Bolt Biotherapeutics' performance and market position to its competitors. Analyze how Bolt Biotherapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Bolt Biotherapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Bolt Biotherapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Bolt Biotherapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Bolt Biotherapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Bolt Biotherapeutics Stock
Researching Bolt Biotherapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 48.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.23. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bolt Biotherapeutics recorded a loss per share of 1.71. The entity last dividend was issued on the August 29, 2014. The firm had 3:2 split on the January 31, 2008.
To determine if Bolt Biotherapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bolt Biotherapeutics' research are outlined below:
| Bolt Biotherapeutics generated a negative expected return over the last 90 days | |
| Bolt Biotherapeutics has some characteristics of a very speculative penny stock | |
| Bolt Biotherapeutics has high historical volatility and very poor performance | |
| Bolt Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 7.88 M. Net Loss for the year was (69.2 M) with loss before overhead, payroll, taxes, and interest of (52.29 M). | |
| Bolt Biotherapeutics currently holds about 176.34 M in cash with (69.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from gurufocus.com: Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides ... |
Bolt Biotherapeutics Quarterly Accounts Payable |
|
Bolt Biotherapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Bolt Biotherapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bolt Biotherapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Bolt Biotherapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Bolt Biotherapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-11 | 2023-03-31 | -0.51 | -0.45 | 0.06 | 11 | ||
2025-03-19 | 2024-12-31 | -0.35 | -0.42 | -0.07 | 20 | ||
2023-11-09 | 2023-09-30 | -0.5 | -0.43 | 0.07 | 14 | ||
2023-03-29 | 2022-12-31 | -0.6 | -0.53 | 0.07 | 11 | ||
2022-08-10 | 2022-06-30 | -0.68 | -0.61 | 0.07 | 10 | ||
2022-05-12 | 2022-03-31 | -0.72 | -0.64 | 0.08 | 11 | ||
2022-03-30 | 2021-12-31 | -0.82 | -0.73 | 0.09 | 10 | ||
2021-08-12 | 2021-06-30 | -0.43 | -0.64 | -0.21 | 48 |
Know Bolt Biotherapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bolt Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bolt Biotherapeutics backward and forwards among themselves. Bolt Biotherapeutics' institutional investor refers to the entity that pools money to purchase Bolt Biotherapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Adar1 Capital Management Llc | 2024-12-31 | 245 K | Fmr Inc | 2024-12-31 | 129.3 K | Citadel Advisors Llc | 2024-12-31 | 79 K | Engineers Gate Manager Lp | 2024-12-31 | 72.4 K | Ubs Group Ag | 2024-12-31 | 66.1 K | Bridgeway Capital Management, Llc | 2024-12-31 | 60.2 K | Prudential Investment Management Inc | 2024-09-30 | 59.2 K | Goldman Sachs Group Inc | 2024-12-31 | 50 K | Velan Capital Investment Management Lp | 2024-12-31 | 50 K | Tang Capital Management Llc | 2024-12-31 | 3.8 M | Vivo Capital, Llc | 2024-12-31 | 3.5 M |
Bolt Biotherapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 16.75 M.Market Cap |
|
Bolt Biotherapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.63) | (0.67) | |
| Return On Capital Employed | (0.87) | (0.92) | |
| Return On Assets | (0.63) | (0.67) | |
| Return On Equity | (1.10) | (1.05) |
Determining Bolt Biotherapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Bolt Biotherapeutics is a good buy. For example, gross profit margin measures Bolt Biotherapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bolt Biotherapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Bolt Biotherapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bolt Biotherapeutics. Check Bolt Biotherapeutics' Beneish M Score to see the likelihood of Bolt Biotherapeutics' management manipulating its earnings.
Evaluate Bolt Biotherapeutics' management efficiency
Bolt Biotherapeutics has return on total asset (ROA) of (0.3176) % which means that it has lost $0.3176 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6499) %, meaning that it created substantial loss on money invested by shareholders. Bolt Biotherapeutics' management efficiency ratios could be used to measure how well Bolt Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.67 in 2025. Return On Capital Employed is likely to drop to -0.92 in 2025. Non Current Liabilities Total is likely to gain to about 46.8 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 16.1 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.50 | 1.13 | |
| Tangible Book Value Per Share | 1.50 | 1.13 | |
| Enterprise Value Over EBITDA | (0.53) | (0.55) | |
| Price Book Value Ratio | 0.36 | 0.38 | |
| Enterprise Value Multiple | (0.53) | (0.55) | |
| Price Fair Value | 0.36 | 0.38 | |
| Enterprise Value | 38.4 M | 36.5 M |
The decision-making processes within Bolt Biotherapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta 0.935 |
Basic technical analysis of Bolt Stock
As of the 25th of March, Bolt Biotherapeutics shows the Mean Deviation of 2.59, standard deviation of 3.51, and Risk Adjusted Performance of (0.04). Bolt Biotherapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Bolt Biotherapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bolt Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bolt Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bolt Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bolt Biotherapeutics' Outstanding Corporate Bonds
Bolt Biotherapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bolt Biotherapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bolt bonds can be classified according to their maturity, which is the date when Bolt Biotherapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US09778PAC95 Corp BondUS09778PAC95 | View | |
| US09778PAA30 Corp BondUS09778PAA30 | View | |
| US09778PAB13 Corp BondUS09778PAB13 | View | |
| US097793AE35 Corp BondUS097793AE35 | View | |
| US097751BX80 Corp BondUS097751BX80 | View | |
| BBDBCN 75 01 FEB 29 Corp BondUS097751BZ39 | View | |
| BOMBARDIER INC 7875 Corp BondUS097751BT78 | View |
Understand Bolt Biotherapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Bolt Biotherapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (1.17) | |||
| Mean Deviation | 2.59 | |||
| Coefficient Of Variation | (1,830) | |||
| Standard Deviation | 3.51 | |||
| Variance | 12.34 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.20) | |||
| Total Risk Alpha | (0.06) | |||
| Treynor Ratio | (1.18) | |||
| Maximum Drawdown | 17.46 | |||
| Value At Risk | (6.45) | |||
| Potential Upside | 5.08 | |||
| Skewness | 0.0962 | |||
| Kurtosis | 0.3018 |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (1.17) | |||
| Mean Deviation | 2.59 | |||
| Coefficient Of Variation | (1,830) | |||
| Standard Deviation | 3.51 | |||
| Variance | 12.34 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.20) | |||
| Total Risk Alpha | (0.06) | |||
| Treynor Ratio | (1.18) | |||
| Maximum Drawdown | 17.46 | |||
| Value At Risk | (6.45) | |||
| Potential Upside | 5.08 | |||
| Skewness | 0.0962 | |||
| Kurtosis | 0.3018 |
Consider Bolt Biotherapeutics' intraday indicators
Bolt Biotherapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bolt Biotherapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 0.44 | |||
| Day Typical Price | 0.44 | |||
| Price Action Indicator | (0) | |||
| Period Momentum Indicator | (0) | |||
| Relative Strength Index | 39.18 |
Bolt Stock media impact
Far too much social signal, news, headlines, and media speculation about Bolt Biotherapeutics that are available to investors today. That information is available publicly through Bolt media outlets and privately through word of mouth or via Bolt internal channels. However, regardless of the origin, that massive amount of Bolt data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Bolt Biotherapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Bolt Biotherapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Bolt Biotherapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Bolt Biotherapeutics alpha.
Bolt Biotherapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Bolt Biotherapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Bolt Biotherapeutics Corporate Management
| Randall Schatzman | CEO Director | Profile | |
| Edith MD | Chief Officer | Profile | |
| Michael Alonso | Senior Research | Profile | |
| MBA CFA | Chief Officer | Profile | |
| Ming Yin | VP Biometrics | Profile | |
| Bruce MD | Sr Medicine | Profile |
Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.